{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HSCT&page=58",
    "query": {
      "condition": "HSCT",
      "page": 58
    },
    "page_size": 10
  },
  "pagination": {
    "page": 58,
    "page_size": 10,
    "total_count": 2476,
    "total_pages": 248,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HSCT&page=59&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=HSCT&page=57&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-14T08:20:13.902Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02169505",
      "title": "Brentuximab Vedotin in High-Risk CD30+ Lymphoma Post Allogeneic Stem Cell Transplantation (AlloSCT)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma"
      ],
      "interventions": [
        {
          "name": "Brentuximab Vedotin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 2,
      "start_date": "2015-05-22",
      "completion_date": "2017-08-14",
      "has_results": true,
      "last_update_posted_date": "2019-11-27",
      "last_synced_at": "2026-11-14T08:20:13.902Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02169505"
    },
    {
      "nct_id": "NCT00768066",
      "title": "The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Stem Cell Transplantation",
        "Ventricular Dysfunction, Left"
      ],
      "interventions": [
        {
          "name": "Autologous human mesenchymal cells (hMSCs)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Autologous human bone marrow cells (hBMCs)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Miami",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "21 Years to 90 Years"
      },
      "enrollment_count": 65,
      "start_date": "2008-08",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2015-12-14",
      "last_synced_at": "2026-11-14T08:20:13.902Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00768066"
    },
    {
      "nct_id": "NCT02269150",
      "title": "Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Allogeneic Hematopoietic Stem Cell"
      ],
      "interventions": [
        {
          "name": "fecal microbiota transplantation (FMT)",
          "type": "BIOLOGICAL"
        },
        {
          "name": "No fecal microbiota transplantation (FMT), routine management",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 59,
      "start_date": "2014-10",
      "completion_date": "2027-10",
      "has_results": false,
      "last_update_posted_date": "2026-11-05",
      "last_synced_at": "2026-11-14T08:20:13.902Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02269150"
    },
    {
      "nct_id": "NCT00179075",
      "title": "Repository: Evaluation of Immunoregulatory Cells in Hematopoietic Stem Cell Transplant",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Hematopoietic Stem Cell Transplantation",
        "Graft vs Host Disease"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Vanderbilt University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 100,
      "start_date": "2003-04",
      "completion_date": "2008-04",
      "has_results": false,
      "last_update_posted_date": "2008-12-15",
      "last_synced_at": "2026-11-14T08:20:13.902Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00179075"
    },
    {
      "nct_id": "NCT03121001",
      "title": "Study of HLA-Haploidentical Stem Cell Transplantation to Treat Clinically Aggressive Sickle Cell Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "ATG",
          "type": "DRUG"
        },
        {
          "name": "fludarabine",
          "type": "DRUG"
        },
        {
          "name": "cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Total body irradiation",
          "type": "RADIATION"
        },
        {
          "name": "Stem cell infusion",
          "type": "PROCEDURE"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE"
      ],
      "sponsor": "University of Illinois Chicago",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": "60 Years",
        "sex": "ALL",
        "summary": "16 Years to 60 Years"
      },
      "enrollment_count": 50,
      "start_date": "2017-03-20",
      "completion_date": "2029-05",
      "has_results": false,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-11-14T08:20:13.902Z",
      "location_count": 1,
      "location_summary": "Chicago, Illinois",
      "locations": [
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03121001"
    },
    {
      "nct_id": "NCT00004177",
      "title": "Radiolabeled Monoclonal Antibody Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory or Recurrent Ovarian Epithelial Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Ovarian Cancer"
      ],
      "interventions": [
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "indium In 111 monoclonal antibody MN-14",
          "type": "RADIATION"
        },
        {
          "name": "yttrium Y 90 monoclonal antibody MN-14",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "PROCEDURE",
        "RADIATION"
      ],
      "sponsor": "Garden State Cancer Center at the Center for Molecular Medicine and Immunology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 80 Years · Female only"
      },
      "enrollment_count": 15,
      "start_date": "1999-08",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-06-22",
      "last_synced_at": "2026-11-14T08:20:13.902Z",
      "location_count": 3,
      "location_summary": "Belleville, New Jersey • Paterson, New Jersey • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Belleville",
          "state": "New Jersey"
        },
        {
          "city": "Paterson",
          "state": "New Jersey"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004177"
    },
    {
      "nct_id": "NCT01326728",
      "title": "Relapsed Malignant Blood Cancer After Allogeneic Hematopoietic Stem Cell Transplantation",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Chronic Myelogenous Leukemia",
        "Acute Myelogenous Leukemia",
        "Acute Lymphoblastic Leukemia",
        "Hodgkins Lymphoma",
        "Non-Hodgkins Lymphoma"
      ],
      "interventions": [
        {
          "name": "Allogeneic stem cell transplant",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "18 Years to 99 Years"
      },
      "enrollment_count": 56,
      "start_date": "2011-03-30",
      "completion_date": "2017-07-14",
      "has_results": true,
      "last_update_posted_date": "2018-06-06",
      "last_synced_at": "2026-11-14T08:20:13.902Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01326728"
    },
    {
      "nct_id": "NCT00048737",
      "title": "Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Lymphoma",
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Zevalin Radioimmunotherapy",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Allogeneic Stem Cell Transplantation",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 70,
      "start_date": "2002-10",
      "completion_date": "2011-12",
      "has_results": true,
      "last_update_posted_date": "2013-06-13",
      "last_synced_at": "2026-11-14T08:20:13.902Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00048737"
    },
    {
      "nct_id": "NCT01966367",
      "title": "CD34+ (Non-Malignant) Stem Cell Selection for Patients Receiving Allogeneic Stem Cell Transplantation",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Bone Marrow Failure Syndrome",
        "Severe Aplastic Anemia",
        "Severe Congenital Neutropenia",
        "Amegakaryocytic Thrombocytopenia",
        "Diamond-Blackfan Anemia",
        "Schwachman Diamond Syndrome",
        "Primary Immunodeficiency Syndromes",
        "Acquired Immunodeficiency Syndromes",
        "Histiocytic Syndrome",
        "Familial Hemophagocytic Lymphocytosis",
        "Lymphohistiocytosis",
        "Macrophage Activation Syndrome",
        "Langerhans Cell Histiocytosis (LCH)",
        "Hemoglobinopathies",
        "Sickle Cell Disease",
        "Sickle Cell-beta-thalassemia"
      ],
      "interventions": [
        {
          "name": "CD34 Stem Cell Selection Therapy",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Diane George",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "40 Years",
        "sex": "ALL",
        "summary": "Up to 40 Years"
      },
      "enrollment_count": 37,
      "start_date": "2013-03",
      "completion_date": "2030-02",
      "has_results": false,
      "last_update_posted_date": "2025-08-14",
      "last_synced_at": "2026-11-14T08:20:13.902Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01966367"
    },
    {
      "nct_id": "NCT00054353",
      "title": "Reduced-Intensity Conditioning Followed By Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Refractory Multiple Myeloma"
      ],
      "interventions": [
        {
          "name": "fludarabine phosphate",
          "type": "DRUG"
        },
        {
          "name": "melphalan",
          "type": "DRUG"
        },
        {
          "name": "total-body irradiation",
          "type": "RADIATION"
        },
        {
          "name": "mycophenolate mofetil",
          "type": "DRUG"
        },
        {
          "name": "cyclosporine",
          "type": "DRUG"
        },
        {
          "name": "nonmyeloablative allogeneic hematopoietic stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "peripheral blood stem cell transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "RADIATION",
        "PROCEDURE",
        "OTHER"
      ],
      "sponsor": "Fred Hutchinson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 16,
      "start_date": "2002-10",
      "completion_date": "2012-10-14",
      "has_results": true,
      "last_update_posted_date": "2017-10-16",
      "last_synced_at": "2026-11-14T08:20:13.902Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00054353"
    }
  ]
}